Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 211 entries
Sorted by: Best Match Show Resources per page
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).

American journal of hematology

Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG.
PMID: 34559902
Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06.

Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA...

Cite
Voorhees PM, Suman VJ, Tuchman SA, et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021;96(12):1595-1603doi: 10.1002/ajh.26361.
Voorhees, P. M., Suman, V. J., Tuchman, S. A., Laubach, J. P., Hassoun, H., Efebera, Y. A., Mulkey, F., Bova-Solem, M., Santo, K., Carlisle, D., McCarthy, P. L., & Richardson, P. G. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). American journal of hematology, 96(12), 1595-1603. https://doi.org/10.1002/ajh.26361
Voorhees, Peter M, et al. "A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)." American journal of hematology vol. 96,12 (2021): 1595-1603. doi: https://doi.org/10.1002/ajh.26361
Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06. PMID: 34559902; PMCID: PMC8713771.
Copy Download .nbib Format: NLM
Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation.

Pediatric blood & cancer

Terry W, Carlisle EM, Mallinger P, Nelson AT, Gordon D, Messinger YH, Field A, Dehner LP, Hill DA, Schultz KAP.
PMID: 34398502
Pediatr Blood Cancer. 2021 Nov;68(11):e29284. doi: 10.1002/pbc.29284. Epub 2021 Aug 16.

A 2-year-old boy presented with a large cystic and solid chest mass arising from the lung, radiographically consistent with pleuropulmonary blastoma (PPB). He underwent right lower lobectomy with resection of a well-circumscribed, mixed solid and cystic mass. The solid...

Cite
Terry W, Carlisle EM, Mallinger P, et al. Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation. Pediatr Blood Cancer. 2021;68(11):e29284doi: 10.1002/pbc.29284.
Terry, W., Carlisle, E. M., Mallinger, P., Nelson, A. T., Gordon, D., Messinger, Y. H., Field, A., Dehner, L. P., Hill, D. A., & Schultz, K. A. P. (2021). Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation. Pediatric blood & cancer, 68(11), e29284. https://doi.org/10.1002/pbc.29284
Terry, William, et al. "Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation." Pediatric blood & cancer vol. 68,11 (2021): e29284. doi: https://doi.org/10.1002/pbc.29284
Terry W, Carlisle EM, Mallinger P, Nelson AT, Gordon D, Messinger YH, Field A, Dehner LP, Hill DA, Schultz KAP. Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation. Pediatr Blood Cancer. 2021 Nov;68(11):e29284. doi: 10.1002/pbc.29284. Epub 2021 Aug 16. PMID: 34398502; PMCID: PMC8463509.
Copy Download .nbib Format: NLM
The successful migration of total joint arthroplasty from the hospital inpatient to outpatient ASC setting.

The Knee

Almand J, Pickering T, Parsell D, Stronach B, Carlisle R, McIntyre L.
PMID: 34871973
Knee. 2021 Dec 03;34:17-23. doi: 10.1016/j.knee.2021.11.004. Epub 2021 Dec 03.

BACKGROUND: This study was undertaken to analyze the clinical results and complication rate of patients undergoing outpatient total joint arthroplasty by a single orthopedic group. All surgeries were performed in the practice-owned ambulatory surgery center (ASC).METHODS: All patients indicated...

Cite
Almand J, Pickering T, Parsell D, et al. The successful migration of total joint arthroplasty from the hospital inpatient to outpatient ASC setting. Knee. 2021;34:17-23doi: 10.1016/j.knee.2021.11.004.
Almand, J., Pickering, T., Parsell, D., Stronach, B., Carlisle, R., & McIntyre, L. (2021). The successful migration of total joint arthroplasty from the hospital inpatient to outpatient ASC setting. The Knee, 3417-23. https://doi.org/10.1016/j.knee.2021.11.004
Almand, Jeff, et al. "The successful migration of total joint arthroplasty from the hospital inpatient to outpatient ASC setting." The Knee vol. 34 (2021): 17-23. doi: https://doi.org/10.1016/j.knee.2021.11.004
Almand J, Pickering T, Parsell D, Stronach B, Carlisle R, McIntyre L. The successful migration of total joint arthroplasty from the hospital inpatient to outpatient ASC setting. Knee. 2021 Dec 03;34:17-23. doi: 10.1016/j.knee.2021.11.004. Epub 2021 Dec 03. PMID: 34871973.
Copy Download .nbib Format: NLM
Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults.

Critical care explorations

Cole AR, Sperotto F, DiNardo JA, Carlisle S, Rivkin MJ, Sleeper LA, Kheir JN.
PMID: 34651133
Crit Care Explor. 2021 Oct 08;3(10):e543. doi: 10.1097/CCE.0000000000000543. eCollection 2021 Oct.

Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled...

Cite
Cole AR, Sperotto F, DiNardo JA, et al. Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults. Crit Care Explor. 2021;3(10):e543doi: 10.1097/CCE.0000000000000543.
Cole, A. R., Sperotto, F., DiNardo, J. A., Carlisle, S., Rivkin, M. J., Sleeper, L. A., & Kheir, J. N. (2021). Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults. Critical care explorations, 3(10), e543. https://doi.org/10.1097/CCE.0000000000000543
Cole, Alexis R, et al. "Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults." Critical care explorations vol. 3,10 (2021): e543. doi: https://doi.org/10.1097/CCE.0000000000000543
Cole AR, Sperotto F, DiNardo JA, Carlisle S, Rivkin MJ, Sleeper LA, Kheir JN. Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults. Crit Care Explor. 2021 Oct 08;3(10):e543. doi: 10.1097/CCE.0000000000000543. eCollection 2021 Oct. PMID: 34651133; PMCID: PMC8505337.
Copy Download .nbib Format: NLM
Publisher Correction: Unexpected involvement of a second rodent species makes impacts of introduced rats more difficult to detect.

Scientific reports

Lambert M, Carlisle S, Cain I, Douse A, Watt L.
PMID: 34711870
Sci Rep. 2021 Oct 28;11(1):21577. doi: 10.1038/s41598-021-00572-4.

No abstract available.

Cite
Lambert M, Carlisle S, Cain I, et al. Publisher Correction: Unexpected involvement of a second rodent species makes impacts of introduced rats more difficult to detect. Sci Rep. 2021;11(1):21577doi: 10.1038/s41598-021-00572-4.
Lambert, M., Carlisle, S., Cain, I., Douse, A., & Watt, L. (2021). Publisher Correction: Unexpected involvement of a second rodent species makes impacts of introduced rats more difficult to detect. Scientific reports, 11(1), 21577. https://doi.org/10.1038/s41598-021-00572-4
Lambert, M, et al. "Publisher Correction: Unexpected involvement of a second rodent species makes impacts of introduced rats more difficult to detect." Scientific reports vol. 11,1 (2021): 21577. doi: https://doi.org/10.1038/s41598-021-00572-4
Lambert M, Carlisle S, Cain I, Douse A, Watt L. Publisher Correction: Unexpected involvement of a second rodent species makes impacts of introduced rats more difficult to detect. Sci Rep. 2021 Oct 28;11(1):21577. doi: 10.1038/s41598-021-00572-4. PMID: 34711870; PMCID: PMC8553806.
Copy Download .nbib Format: NLM
Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.

Molecular therapy oncolytics

Hill C, Grundy M, Bau L, Wallington S, Balkaran J, Ramos V, Fisher K, Seymour L, Coussios C, Carlisle R.
PMID: 33869742
Mol Ther Oncolytics. 2021 Mar 17;21:47-61. doi: 10.1016/j.omto.2021.03.011. eCollection 2021 Jun 25.

Vaccinia virus (VV) is a powerful tool for cancer treatment with the potential for tumor tropism, efficient cell-to-cell spread, rapid replication in cancer cells, and stimulation of anti-tumor immunity. It has a well-defined safety profile and is being assessed...

Cite
Hill C, Grundy M, Bau L, et al. Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Mol Ther Oncolytics. 2021;21:47-61doi: 10.1016/j.omto.2021.03.011.
Hill, C., Grundy, M., Bau, L., Wallington, S., Balkaran, J., Ramos, V., Fisher, K., Seymour, L., Coussios, C., & Carlisle, R. (2021). Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Molecular therapy oncolytics, 2147-61. https://doi.org/10.1016/j.omto.2021.03.011
Hill, Claudia, et al. "Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus." Molecular therapy oncolytics vol. 21 (2021): 47-61. doi: https://doi.org/10.1016/j.omto.2021.03.011
Hill C, Grundy M, Bau L, Wallington S, Balkaran J, Ramos V, Fisher K, Seymour L, Coussios C, Carlisle R. Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Mol Ther Oncolytics. 2021 Mar 17;21:47-61. doi: 10.1016/j.omto.2021.03.011. eCollection 2021 Jun 25. PMID: 33869742; PMCID: PMC8026752.
Copy Download .nbib Format: NLM
Achievements and needs for the climate change scenario framework.

Nature climate change

O'Neill BC, Carter TR, Ebi K, Harrison PA, Kemp-Benedict E, Kok K, Kriegler E, Preston BL, Riahi K, Sillmann J, van Ruijven BJ, van Vuuren D, Carlisle D, Conde C, Fuglestvedt J, Green C, Hasegawa T, Leininger J, Monteith S, Pichs-Madruga R.
PMID: 33262808
Nat Clim Chang. 2020 Nov 25;1-11. doi: 10.1038/s41558-020-00952-0. Epub 2020 Nov 25.

Long-term global scenarios have underpinned research and assessment of global environmental change for four decades. Over the past ten years, the climate change research community has developed a scenario framework combining alternative futures of climate and society to facilitate...

Cite
O'Neill BC, Carter TR, Ebi K, et al. Achievements and needs for the climate change scenario framework. Nat Clim Chang. 2020;1-11doi: 10.1038/s41558-020-00952-0.
O'Neill, B. C., Carter, T. R., Ebi, K., Harrison, P. A., Kemp-Benedict, E., Kok, K., Kriegler, E., Preston, B. L., Riahi, K., Sillmann, J., van Ruijven, B. J., van Vuuren, D., Carlisle, D., Conde, C., Fuglestvedt, J., Green, C., Hasegawa, T., Leininger, J., Monteith, S., & Pichs-Madruga, R. (2020). Achievements and needs for the climate change scenario framework. Nature climate change, 1-11. https://doi.org/10.1038/s41558-020-00952-0
O'Neill, Brian C, et al. "Achievements and needs for the climate change scenario framework." Nature climate change vol. (2020): 1-11. doi: https://doi.org/10.1038/s41558-020-00952-0
O'Neill BC, Carter TR, Ebi K, Harrison PA, Kemp-Benedict E, Kok K, Kriegler E, Preston BL, Riahi K, Sillmann J, van Ruijven BJ, van Vuuren D, Carlisle D, Conde C, Fuglestvedt J, Green C, Hasegawa T, Leininger J, Monteith S, Pichs-Madruga R. Achievements and needs for the climate change scenario framework. Nat Clim Chang. 2020 Nov 25;1-11. doi: 10.1038/s41558-020-00952-0. Epub 2020 Nov 25. PMID: 33262808; PMCID: PMC7688299.
Copy Download .nbib Format: NLM
Trained Immunity in .

Frontiers in microbiology

Kulkarni A, Pandey A, Trainor P, Carlisle S, Chhilar JS, Yu W, Moon A, Xu J.
PMID: 33995307
Front Microbiol. 2021 Apr 30;12:649213. doi: 10.3389/fmicb.2021.649213. eCollection 2021.

Mosquitoes have evolved an effective innate immune system. The mosquito gut accommodates various microbes, which play a crucial role in shaping the mosquito immune system during evolution. The resident bacteria in the gut microbiota play an essential role in...

Cite
Kulkarni A, Pandey A, Trainor P, et al. Trained Immunity in . Front Microbiol. 2021;12:649213doi: 10.3389/fmicb.2021.649213.
Kulkarni, A., Pandey, A., Trainor, P., Carlisle, S., Chhilar, J. S., Yu, W., Moon, A., & Xu, J. (2021). Trained Immunity in . Frontiers in microbiology, 12649213. https://doi.org/10.3389/fmicb.2021.649213
Kulkarni, Aditi, et al. "Trained Immunity in ." Frontiers in microbiology vol. 12 (2021): 649213. doi: https://doi.org/10.3389/fmicb.2021.649213
Kulkarni A, Pandey A, Trainor P, Carlisle S, Chhilar JS, Yu W, Moon A, Xu J. Trained Immunity in . Front Microbiol. 2021 Apr 30;12:649213. doi: 10.3389/fmicb.2021.649213. eCollection 2021. PMID: 33995307; PMCID: PMC8121176.
Copy Download .nbib Format: NLM
Efficacy of relatively low-cost ultraviolet-C light devices against .

Infection control and hospital epidemiology

Pearlmutter BS, Haq MF, Cadnum JL, Jencson AL, Carlisle M, Donskey CJ.
PMID: 34011417
Infect Control Hosp Epidemiol. 2021 May 20;1-5. doi: 10.1017/ice.2021.206. Epub 2021 May 20.

BACKGROUND: Ultraviolet-C (UV-C) light devices could be useful to reduce environmental contamination with Candida auris. However, variable susceptibility of C. auris strains to UV-C has been reported, and the high cost of many devices limits their use in resource-limited...

Cite
Pearlmutter BS, Haq MF, Cadnum JL, et al. Efficacy of relatively low-cost ultraviolet-C light devices against . Infect Control Hosp Epidemiol. 2021;1-5doi: 10.1017/ice.2021.206.
Pearlmutter, B. S., Haq, M. F., Cadnum, J. L., Jencson, A. L., Carlisle, M., & Donskey, C. J. (2021). Efficacy of relatively low-cost ultraviolet-C light devices against . Infection control and hospital epidemiology, 1-5. https://doi.org/10.1017/ice.2021.206
Pearlmutter, Basya S, et al. "Efficacy of relatively low-cost ultraviolet-C light devices against ." Infection control and hospital epidemiology vol. (2021): 1-5. doi: https://doi.org/10.1017/ice.2021.206
Pearlmutter BS, Haq MF, Cadnum JL, Jencson AL, Carlisle M, Donskey CJ. Efficacy of relatively low-cost ultraviolet-C light devices against . Infect Control Hosp Epidemiol. 2021 May 20;1-5. doi: 10.1017/ice.2021.206. Epub 2021 May 20. PMID: 34011417.
Copy Download .nbib Format: NLM
Common insecticide disrupts aquatic communities: A mesocosm-to-field ecological risk assessment of fipronil and its degradates in U.S. streams.

Science advances

Miller JL, Schmidt TS, Van Metre PC, Mahler BJ, Sandstrom MW, Nowell LH, Carlisle DM, Moran PW.
PMID: 33097542
Sci Adv. 2020 Oct 23;6(43). doi: 10.1126/sciadv.abc1299. Print 2020 Oct.

Insecticides in streams are increasingly a global concern, yet information on safe concentrations for aquatic ecosystems is sparse. In a 30-day mesocosm experiment exposing native benthic aquatic invertebrates to the common insecticide fipronil and four degradates, fipronil compounds caused...

Cite
Miller JL, Schmidt TS, Van Metre PC, et al. Common insecticide disrupts aquatic communities: A mesocosm-to-field ecological risk assessment of fipronil and its degradates in U.S. streams. Sci Adv. 2020;6(43)doi: 10.1126/sciadv.abc1299.
Miller, J. L., Schmidt, T. S., Van Metre, P. C., Mahler, B. J., Sandstrom, M. W., Nowell, L. H., Carlisle, D. M., & Moran, P. W. (2020). Common insecticide disrupts aquatic communities: A mesocosm-to-field ecological risk assessment of fipronil and its degradates in U.S. streams. Science advances, 6(43), . https://doi.org/10.1126/sciadv.abc1299
Miller, Janet L, et al. "Common insecticide disrupts aquatic communities: A mesocosm-to-field ecological risk assessment of fipronil and its degradates in U.S. streams." Science advances vol. 6,43 (2020). doi: https://doi.org/10.1126/sciadv.abc1299
Miller JL, Schmidt TS, Van Metre PC, Mahler BJ, Sandstrom MW, Nowell LH, Carlisle DM, Moran PW. Common insecticide disrupts aquatic communities: A mesocosm-to-field ecological risk assessment of fipronil and its degradates in U.S. streams. Sci Adv. 2020 Oct 23;6(43). doi: 10.1126/sciadv.abc1299. Print 2020 Oct. PMID: 33097542; PMCID: PMC7608825.
Copy Download .nbib Format: NLM
Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems.

Advanced therapeutics

DeJulius CR, Gulati S, Hasty KA, Crofford LJ, Duvall CL.
PMID: 33709019
Adv Ther (Weinh). 2021 Jan;4(1). doi: 10.1002/adtp.202000088. Epub 2020 Sep 28.

Osteoarthritis (OA) is a degenerative disease of the joints and a leading cause of physical disability in adults. Intra-articular (IA) therapy is a popular treatment strategy for localized, single-joint OA; however, small-molecule drugs such as corticosteroids do not provide...

Cite
DeJulius CR, Gulati S, Hasty KA, et al. Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems. Adv Ther (Weinh). 2020;4(1)doi: 10.1002/adtp.202000088.
DeJulius, C. R., Gulati, S., Hasty, K. A., Crofford, L. J., & Duvall, C. L. (2021). Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems. Advanced therapeutics, 4(1), . https://doi.org/10.1002/adtp.202000088
DeJulius, Carlisle R, et al. "Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems." Advanced therapeutics vol. 4,1 (2021). doi: https://doi.org/10.1002/adtp.202000088
DeJulius CR, Gulati S, Hasty KA, Crofford LJ, Duvall CL. Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems. Adv Ther (Weinh). 2021 Jan;4(1). doi: 10.1002/adtp.202000088. Epub 2020 Sep 28. PMID: 33709019; PMCID: PMC7941755.
Copy Download .nbib Format: NLM
Corrigendum: Quantifying overlap between the Deepwater Horizon oil spill and predicted bluefin tuna spawning habitat in the Gulf of Mexico.

Scientific reports

Hazen EL, Carlisle AB, Wilson SG, Ganong JE, Castleton MR, Schallert RJ, Stokesbury MJ, Bograd SJ, Block BA.
PMID: 27830721
Sci Rep. 2016 Nov 10;6:36689. doi: 10.1038/srep36689.

No abstract available.

Cite
Hazen EL, Carlisle AB, Wilson SG, et al. Corrigendum: Quantifying overlap between the Deepwater Horizon oil spill and predicted bluefin tuna spawning habitat in the Gulf of Mexico. Sci Rep. 2016;6:36689doi: 10.1038/srep36689.
Hazen, E. L., Carlisle, A. B., Wilson, S. G., Ganong, J. E., Castleton, M. R., Schallert, R. J., Stokesbury, M. J., Bograd, S. J., & Block, B. A. (2016). Corrigendum: Quantifying overlap between the Deepwater Horizon oil spill and predicted bluefin tuna spawning habitat in the Gulf of Mexico. Scientific reports, 636689. https://doi.org/10.1038/srep36689
Hazen, Elliott L, et al. "Corrigendum: Quantifying overlap between the Deepwater Horizon oil spill and predicted bluefin tuna spawning habitat in the Gulf of Mexico." Scientific reports vol. 6 (2016): 36689. doi: https://doi.org/10.1038/srep36689
Hazen EL, Carlisle AB, Wilson SG, Ganong JE, Castleton MR, Schallert RJ, Stokesbury MJ, Bograd SJ, Block BA. Corrigendum: Quantifying overlap between the Deepwater Horizon oil spill and predicted bluefin tuna spawning habitat in the Gulf of Mexico. Sci Rep. 2016 Nov 10;6:36689. doi: 10.1038/srep36689. PMID: 27830721; PMCID: PMC5103198.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 211 entries